Considering the reported IL-1β signal reported in breast cancer, we sought to investigate whether NLRP3 activation is involved in the production of IL-1β in breast cancer and whether its inhibition would reduce the increased IL-1β signal and enhance anti-PD-1 therapy. Here, NLRP3 is linked to breast cancer.